<DOC>
	<DOC>NCT02121899</DOC>
	<brief_summary>This registry is intended to measure the effect of myPlan Lung Cancerâ„¢ test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC. The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006). This registry is specific to Oncologists (ONC006).</brief_summary>
	<brief_title>Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Diagnosis of early stage nonsmall cell lung adenocarcinoma Subpopulation staging (IA, IB or IIA) as judged by the standard of practice at the investigational site Resection of tumor within previous 2 months of enrollment ECOG performance of 02 A minimum life expectancy of six months Exclusion Criteria Previous myPlan Lung Cancer test performed Preoperative radiation or chemotherapy for NSCLC Postoperative radiation or chemotherapy for NSCLC Enrollment in a separate clinical trial restricting treatment options Unable to provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Registry</keyword>
</DOC>